Short Interest in Aclarion, Inc. (NASDAQ:ACON) Increases By 210.3%

Aclarion, Inc. (NASDAQ:ACON) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,230,000 shares, a growth of 210.3% from the November 30th total of 396,400 shares. Based on an average daily trading volume, of 650,100 shares, the days-to-cover ratio is presently 1.9 days. Approximately 11.8% of the company’s shares are short sold.

Aclarion Stock Performance

ACON stock remained flat at $0.13 during trading hours on Thursday. The company’s stock had a trading volume of 221,626 shares, compared to its average volume of 1,399,640. The firm’s 50 day simple moving average is $0.17 and its 200-day simple moving average is $0.22. Aclarion has a 52-week low of $0.10 and a 52-week high of $6.75.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ACON shares. Maxim Group reiterated a “hold” rating on shares of Aclarion in a report on Friday, December 13th. Ascendiant Capital Markets cut their price target on shares of Aclarion from $1.50 to $1.30 and set a “buy” rating on the stock in a research note on Wednesday, November 27th.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.